Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

It was the view of the reference centre directors at the special meeting on 13 May 1983 that cryoprecipitate was not particularly easy to use as there was no guarantee of the amount of Factor 8 in each bag, and it was not a particularly useful therapeutic option for major surgery or major bleeds.

Published on: 27 September, 2024

Inquiry publishes timetable for further evidence from panels and expert groups

Published on: 31 August, 2022

The results of a survey between Sheffield and the Royal Free on chronic hepatitis showed that approximately one third of the patients studied had the appearance of chronic active (aggressive) hepatitis.

Published on: 27 September, 2024

A letter to The Lancet in 1982 reported that "we have previously shown that there is a high incidence of chronic liver disease among patients receiving blood product concentrates even in the absence of any symptoms."

Published on: 27 September, 2024

The annual return for 1976 showed the Sheffield Haemophilia Centre treating its patients with cryoprecipitate, NHS Factor 8 and commercial concentrates.

Published on: 27 September, 2024

It was noted in the Annual Returns for Sheffield Haemophilia Centre for 1977 'that "home treatment packs' from ARMOUR have been used most of the time for home therapy."

Published on: 27 September, 2024

In 1979 the Sheffield Haemophilia Centre's return recorded no cryoprecipitate use at all for people with Haemophilia A.

Published on: 27 September, 2024

Annual returns for Sheffield Haemophilia Centre in 1980 recorded that a small amount of cryoprecipitate was used, but the mainstay of treatment was commercial concentrate

Published on: 27 September, 2024

In 1980, in the Sheffield Haemophilia Centre, a small amount of cryoprecipitate was used, but the majority of treatment was commercial concentrate (4,690 units of cryoprecipitate; 141,775 units of NHS concentrate; 800,852 units of commercial concentrates (Factorate, Hemofil, Kryobulin)).

Published on: 27 September, 2024

Professor Eric Preston stated in his statement that cryoprecipitate was not a treatment option for severe haemophiliacs, and that this did not change over time.

Published on: 27 September, 2024

In Birmingham, Haemophilia care was split between the Children's Hospital and the Queen Elizabeth Hospital. They were jointly designated as a haemophilia centre in the 1970s

Published on: 27 September, 2024

In 1976 Dr Frank Hill succeeded Dr Jillian Mann as director at the Children's Hospital; Dr John Stuart was director at QEH until 1983 when he was succeeded by Dr Ian Franklin

Published on: 27 September, 2024

The West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs met regularly throughout the 1970s to discuss issues relating to supply

Published on: 27 September, 2024

In December 1975, the West Midlands Regional Health Authority recorded difficulties in producing sufficient plasma and it was agreed that commercial Factor 8 (Kryobulin) would need to be purchased at an annual cost to the region of £350,000.

Published on: 10 October, 2024

Demand for cryoprecipitate was going down and NHS concentrates were not being used at the rate that had been predicted

Published on: 27 September, 2024

In 1976 the Queen Elizabeth Hospital had used 500,000 units of commercial Factor 8 for home treatment, because all the NHS product having been used for treatment in hospital and for dental cases.

Published on: 27 September, 2024

During 1977 the Queen Elizabeth Hospital used significant amounts of commercial Factor 8 (almost double the amount from the previous year) as well as NHS Factor 8 (at a similar level to the previous year)

Published on: 27 September, 2024

At a Working Party meeting Dr Stuart stated that during 1976 Queen Elizabeth Hospital had used 500,000 units of commercial Factor 8 for home treatment, with all the NHS product having been used for treatment in hospital and for dental cases. He stated that his preference was to have all his Factor 8 from the same source, and that he was minded to discontinue cryoprecipitate as a home treatment and use NHS product instead.

Published on: 27 September, 2024

During 1977 Queen Elizabeth Hospital used significant amounts of commercial Factor 8 as well as NHS Factor 8

Published on: 27 September, 2024

Dr Stuart of Queen Elizabeth Hospital stated that only a third of Queen Elizabeth Hospital's Factor 8 product was received from the Lister, meaning the two-thirds shortfall had to be made up with commercial concentrates.

Published on: 27 September, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2323
  • Page 2324
  • Page 2325
  • Page 2326
  • Current page 2327
  • Page 2328
  • Page 2329
  • Page 2330
  • Page 2331
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.